View Future GrowthKMPHARMACEUTICALLtd 과거 순이익 실적과거 기준 점검 0/6KMPHARMACEUTICALLtd 의 수입은 연평균 -35.6%의 비율로 감소해 온 반면, Personal Products 산업은 연평균 20.2%의 비율로 증가했습니다. 매출은 연평균 9.1%의 비율로 감소해 왔습니다.핵심 정보-35.57%순이익 성장률-34.90%주당순이익(EPS) 성장률Personal Products 산업 성장률3.77%매출 성장률-9.13%자기자본이익률-14.50%순이익률-24.29%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트Reported Earnings • Jun 01First quarter 2026 earnings released: ₩30.00 loss per share (vs ₩30.00 loss in 1Q 2025)First quarter 2026 results: ₩30.00 loss per share (in line with 1Q 2025). Revenue: ₩4.47b (up 9.5% from 1Q 2025). Net loss: ₩834.2m (loss widened 1.2% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings.모든 업데이트 보기Recent updatesReported Earnings • Jun 01First quarter 2026 earnings released: ₩30.00 loss per share (vs ₩30.00 loss in 1Q 2025)First quarter 2026 results: ₩30.00 loss per share (in line with 1Q 2025). Revenue: ₩4.47b (up 9.5% from 1Q 2025). Net loss: ₩834.2m (loss widened 1.2% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings.New Risk • Apr 13New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 400% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩2.0b free cash flow). Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings have declined by 41% per year over the past 5 years. Shareholders have been substantially diluted in the past year (400% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩72.1b market cap, or US$48.5m).공고 • Mar 26KM Pharmaceutical Co., Ltd. Expands Functional Skincare And Oral Care Product PortfolioKM Pharmaceutical Co. Ltd. is strengthening its global position by expanding into high-value functional product categories across haircare, skincare, and oral care. KM Pharmaceutical is strategically expanding its product portfolio to focus on functional and OTC-driven categories with strong global demand. In haircare, the company is developing products targeting: Hair loss symptom relief (functional scalp care), Scalp inflammation soothing, Scalp barrier strengthening. In skincare, the company is strengthening its functional cosmetic lineup with: Brightening (whitening) solutions, Anti-wrinkle and firming products, Skin barrier repair and strengthening, Anti-inflammatory and soothing formulations for sensitive skin. In oral care, KM Pharmaceutical is expanding its OTC-focused portfolio with: Teeth whitening solutions, Gum disease prevention products, Gingivitis and periodontitis prevention formulations. These categories reflect the company's strategic direction toward high-efficacy, clinically positioned products that align with global consumer demand for functional and results-driven personal care. Skincare continues to be a key growth driver for KM Pharmaceutical's global business.공고 • Mar 17KMPHARMACEUTICAL Co.,Ltd., Annual General Meeting, Mar 31, 2026KMPHARMACEUTICAL Co.,Ltd., Annual General Meeting, Mar 31, 2026, at 08:00 Tokyo Standard Time. Location: conference room, 121, pyeongtaekhang-ro 268beon-gil, poseung-eup, gyeonggi-do, pyeongtaek South Korea분석 기사 • Feb 06Is KMPHARMACEUTICALLtd (KOSDAQ:225430) Using Debt Sensibly?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...New Risk • Feb 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩2.1b free cash flow). Earnings have declined by 45% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩18.6b market cap, or US$12.7m).New Risk • Jan 06New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩14.4b (US$9.94m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩2.1b free cash flow). Earnings have declined by 45% per year over the past 5 years. Market cap is less than US$10m (₩14.4b market cap, or US$9.94m).New Risk • May 21New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risk Market cap is less than US$100m (₩16.6b market cap, or US$11.9m).공고 • Mar 18KMPHARMACEUTICAL Co.,Ltd., Annual General Meeting, Mar 31, 2025KMPHARMACEUTICAL Co.,Ltd., Annual General Meeting, Mar 31, 2025, at 08:00 Tokyo Standard Time. Location: conference room, 121, pyeongtaekhang-ro 268beon-gil, poseung-eup, gyeonggi-do, pyeongtaek South KoreaNew Risk • Mar 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩18.5b market cap, or US$12.8m).New Risk • Feb 28New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩14.5b (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (₩14.5b market cap, or US$9.97m).Is New 90 Day High Low • Feb 23New 90-day low: ₩2,675The company is down 20% from its price of ₩3,325 on 25 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 9.0% over the same period.Is New 90 Day High Low • Jan 18New 90-day low: ₩2,795The company is down 7.0% from its price of ₩3,020 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 10.0% over the same period.Is New 90 Day High Low • Dec 23New 90-day low: ₩2,815The company is down 5.0% from its price of ₩2,965 on 24 September 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 12% over the same period.Is New 90 Day High Low • Oct 26New 90-day low: ₩2,845The company is down 16% from its price of ₩3,380 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 6.0% over the same period.Is New 90 Day High Low • Sep 22New 90-day low: ₩3,125The company is down 3.0% from its price of ₩3,235 on 24 June 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 11% over the same period.매출 및 비용 세부 내역KMPHARMACEUTICALLtd가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이KOSDAQ:A225430 매출, 비용 및 순이익 (KRW Millions)날짜매출순이익일반관리비연구개발비31 Mar 2616,379-3,9786,20289931 Dec 2515,990-3,9685,97594430 Sep 2515,093-4,6786,04483730 Jun 2514,015-4,6125,80271931 Mar 2514,088-4,8816,40762831 Dec 2414,475-4,5736,39256030 Sep 2414,545-3,6486,07247830 Jun 2415,295-3,2086,05139731 Mar 2417,095-1,8175,39133731 Dec 2317,770-1,3205,23029830 Sep 2317,580-2,7766,87132130 Jun 2317,711-3,2666,43437631 Mar 2316,044-3,9056,05541431 Dec 2215,631-3,9255,99645030 Sep 2218,805-1,8643,91749230 Jun 2220,000-1,2713,98747331 Mar 2222,043-6704,25244531 Dec 2122,705-6114,01440530 Sep 2121,335-2293,56132030 Jun 2121,164-153,78927731 Mar 2122,518734,01627231 Dec 2022,9284714,37130730 Sep 2022,844-5125,82637130 Jun 2023,443-5526,62530431 Mar 2021,326-6126,34942131 Dec 1920,338-9026,53436830 Sep 1919,7312335,64729130 Jun 1918,406-12,3194,48929131 Mar 1917,477-12,5614,53715831 Dec 1817,302-12,3303,81017830 Sep 1816,654-12,0043,26416131 Dec 1716,9151,7523,173100양질의 수익: A225430 은(는) 현재 수익성이 없습니다.이익 마진 증가: A225430는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: A225430은 수익성이 없으며 지난 5년 동안 손실이 연평균 35.6% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 A225430의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: A225430은 수익성이 없어 지난 해 수익 성장률을 Personal Products 업계(20.6%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: A225430는 현재 수익성이 없으므로 자본 수익률이 음수(-14.5%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YHousehold 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/13 17:05종가2026/07/13 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스KMPHARMACEUTICAL Co.,Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Jun 01First quarter 2026 earnings released: ₩30.00 loss per share (vs ₩30.00 loss in 1Q 2025)First quarter 2026 results: ₩30.00 loss per share (in line with 1Q 2025). Revenue: ₩4.47b (up 9.5% from 1Q 2025). Net loss: ₩834.2m (loss widened 1.2% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Jun 01First quarter 2026 earnings released: ₩30.00 loss per share (vs ₩30.00 loss in 1Q 2025)First quarter 2026 results: ₩30.00 loss per share (in line with 1Q 2025). Revenue: ₩4.47b (up 9.5% from 1Q 2025). Net loss: ₩834.2m (loss widened 1.2% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings.
New Risk • Apr 13New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 400% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩2.0b free cash flow). Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings have declined by 41% per year over the past 5 years. Shareholders have been substantially diluted in the past year (400% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩72.1b market cap, or US$48.5m).
공고 • Mar 26KM Pharmaceutical Co., Ltd. Expands Functional Skincare And Oral Care Product PortfolioKM Pharmaceutical Co. Ltd. is strengthening its global position by expanding into high-value functional product categories across haircare, skincare, and oral care. KM Pharmaceutical is strategically expanding its product portfolio to focus on functional and OTC-driven categories with strong global demand. In haircare, the company is developing products targeting: Hair loss symptom relief (functional scalp care), Scalp inflammation soothing, Scalp barrier strengthening. In skincare, the company is strengthening its functional cosmetic lineup with: Brightening (whitening) solutions, Anti-wrinkle and firming products, Skin barrier repair and strengthening, Anti-inflammatory and soothing formulations for sensitive skin. In oral care, KM Pharmaceutical is expanding its OTC-focused portfolio with: Teeth whitening solutions, Gum disease prevention products, Gingivitis and periodontitis prevention formulations. These categories reflect the company's strategic direction toward high-efficacy, clinically positioned products that align with global consumer demand for functional and results-driven personal care. Skincare continues to be a key growth driver for KM Pharmaceutical's global business.
공고 • Mar 17KMPHARMACEUTICAL Co.,Ltd., Annual General Meeting, Mar 31, 2026KMPHARMACEUTICAL Co.,Ltd., Annual General Meeting, Mar 31, 2026, at 08:00 Tokyo Standard Time. Location: conference room, 121, pyeongtaekhang-ro 268beon-gil, poseung-eup, gyeonggi-do, pyeongtaek South Korea
분석 기사 • Feb 06Is KMPHARMACEUTICALLtd (KOSDAQ:225430) Using Debt Sensibly?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
New Risk • Feb 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩2.1b free cash flow). Earnings have declined by 45% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩18.6b market cap, or US$12.7m).
New Risk • Jan 06New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩14.4b (US$9.94m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩2.1b free cash flow). Earnings have declined by 45% per year over the past 5 years. Market cap is less than US$10m (₩14.4b market cap, or US$9.94m).
New Risk • May 21New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risk Market cap is less than US$100m (₩16.6b market cap, or US$11.9m).
공고 • Mar 18KMPHARMACEUTICAL Co.,Ltd., Annual General Meeting, Mar 31, 2025KMPHARMACEUTICAL Co.,Ltd., Annual General Meeting, Mar 31, 2025, at 08:00 Tokyo Standard Time. Location: conference room, 121, pyeongtaekhang-ro 268beon-gil, poseung-eup, gyeonggi-do, pyeongtaek South Korea
New Risk • Mar 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩18.5b market cap, or US$12.8m).
New Risk • Feb 28New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩14.5b (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (₩14.5b market cap, or US$9.97m).
Is New 90 Day High Low • Feb 23New 90-day low: ₩2,675The company is down 20% from its price of ₩3,325 on 25 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 9.0% over the same period.
Is New 90 Day High Low • Jan 18New 90-day low: ₩2,795The company is down 7.0% from its price of ₩3,020 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Dec 23New 90-day low: ₩2,815The company is down 5.0% from its price of ₩2,965 on 24 September 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 12% over the same period.
Is New 90 Day High Low • Oct 26New 90-day low: ₩2,845The company is down 16% from its price of ₩3,380 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 6.0% over the same period.
Is New 90 Day High Low • Sep 22New 90-day low: ₩3,125The company is down 3.0% from its price of ₩3,235 on 24 June 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 11% over the same period.